Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Core Insights - Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases [1] - The company announced its corporate priorities and pipeline advancement milestones for 2026, emphasizing the development of novel XmAb® drug candidates [1] - Xencor aims to create potential first-in-class and best-in-class medicines, building on the momentum from 2025 [1]